Is Dying From Liver Failure Painful?

Pain is one of the most common symptoms in end-stage liver disease, reported by anywhere from 30% to more than 80% of patients depending on the study and stage of illness. A systematic review and meta-analysis of patients with end-stage liver disease found pain prevalence ranging between 30% and 79%, with more than half of advanced cirrhosis patients experiencing pain at least daily.¹ But the question of whether dying from liver failure is painful turns out to be more layered than a simple yes. The pain itself is real and widespread, yet the disease also progressively dulls consciousness in ways that complicate both the experience and its treatment.

How Common Pain Is and Where It Shows Up

Pain in advanced liver disease tends to cluster in a few predictable places. A cross-sectional survey of cirrhosis patients found that over 86% reported pain at the time of the survey, with the abdomen as the most frequent site (about 83%), followed by the lower legs (roughly 59%) and lower back (around 57%).² Pain at its worst in the previous 24 hours averaged around 6 out of 10, which falls into the moderate range, while the overall composite pain score across the day averaged about 4 out of 10, closer to mild.² That average masks a wide spread. Some patients hover near the low end, while others deal with severe peaks that punctuate an already exhausting illness.

Pain is also not the only distressing symptom. When researchers asked patients with end-stage liver disease to rank what bothered them most, the top four were pain, lack of energy, feeling drowsy, and difficulty sleeping.³ These symptoms feed into one another: poor sleep worsens pain perception, pain saps energy, and drowsiness makes it harder to advocate for your own care. The cumulative burden matters as much as any single symptom.

What Actually Causes the Pain

The liver itself has almost no pain-sensing nerves inside its tissue. What does have nerves is the thin capsule surrounding the liver, called Glisson’s capsule. In cirrhosis, this capsule thickens dramatically. Researchers measuring capsule samples found that cirrhotic livers had capsules roughly three times thicker than normal controls.⁴ As the diseased liver swells, it stretches this thickened capsule, activating pain fibers. The result is a deep, diffuse ache in the upper right abdomen that can be difficult for patients to pinpoint precisely.

But capsular stretch is only part of the picture. The high prevalence of abdominal pain in cirrhosis is also driven by ascites (fluid buildup in the abdomen) and splenomegaly (an enlarged spleen).⁵ Ascites can be especially miserable. Liters of fluid accumulate in the abdominal cavity, creating pressure that makes it hard to eat, breathe, or find a comfortable position. Draining this fluid through a procedure called paracentesis provides temporary relief, but the fluid often returns within days or weeks, and repeated draining sessions become a fixture of late-stage care.⁶

Muscle cramps are another painful companion that rarely gets the attention it deserves. A study of 150 cirrhosis patients found that about two-thirds reported muscle cramps in the preceding three months. These cramps independently worsened quality of life to a degree comparable to hepatic encephalopathy, which is widely considered the most debilitating complication of liver failure.⁷ The cramps tend to come on without warning, and no clear clinical predictor has been identified for who will get them or how severe they will be.

Itching, Breathlessness, and Other Non-Pain Suffering

Not all suffering in liver failure registers as “pain” in the conventional sense, but some of the non-pain symptoms can be equally unbearable. Cholestatic pruritus, the intense itching associated with impaired bile flow, can drive patients to the edge of desperation. The exact trigger remains elusive even to researchers. Bile salts, histamine, endogenous opioids, and a compound called lysophosphatidic acid have all been proposed as the itch-causing agent, but no single substance has been conclusively identified as the dominant cause.⁸ What is clear is that the itching does not respond reliably to standard antihistamines, and some patients scratch themselves raw.⁹

A more recent review noted that total bile acid and bilirubin levels are actually unlikely to be the dominant itch drivers, pointing instead toward certain lysophospholipids and sulfated progesterone metabolites.¹⁰ For the patient, the clinical reality is the same regardless of the mechanism: the itching can be relentless, and treatments that work well for one person may do nothing for the next.

Breathing difficulties add another layer of distress. When fluid crosses from the abdominal cavity into the chest space, a condition called hepatic hydrothorax, patients can develop cough, chest pain, and shortness of breath even at rest. About a third of patients with hepatic hydrothorax experience breathlessness at rest, and some develop life-threatening respiratory distress.¹¹ The sensation of not being able to catch your breath is distressing in a way that is categorically different from pain, yet for many patients it is the symptom they fear most.

How Encephalopathy Changes the Experience

Here is where dying from liver failure diverges sharply from many other terminal illnesses. As the liver fails, toxins that it normally clears from the blood, especially ammonia, build up and affect the brain. This process, hepatic encephalopathy, progressively blunts consciousness. It can begin with subtle personality changes and confusion, progress through disorientation and sleepiness, and eventually lead to deep unresponsiveness resembling coma.¹²

For families, the question that hangs in the room is often: can they still feel pain? Research on sensory perception in hepatic encephalopathy offers a partial and somewhat reassuring answer. Patients with more advanced encephalopathy show impaired ability to detect temperature changes, particularly cold. They needed larger temperature differences to distinguish warm from cold stimuli.¹³ Even in the earlier stages, before overt confusion sets in, patients with minimal hepatic encephalopathy already show decreased thermal sensitivity and slower reaction times.¹⁴

However, and this is important, pain detection thresholds for mechanical stimuli were not significantly changed in these same patients.¹³ So encephalopathy does not simply erase pain. It blunts certain sensory pathways and progressively dims awareness, but the mechanical and visceral pain from a distended abdomen or cramping muscles may still register to some degree, even as the patient becomes less able to communicate it. This is one of the most difficult aspects for caregivers: a patient who cannot respond may still be uncomfortable, and a patient who appears calm may be sedated by the disease itself rather than by adequate pain relief.

The movement patterns that emerge during encephalopathy can also be alarming to watch. Patients may develop involuntary jerking movements, called myoclonus, which are a hallmark of the hyperkinetic movement abnormalities seen in hepatic encephalopathy. These are distinct from the rigid, slowed movements of a separate condition called acquired hepatocerebral degeneration, which can coexist in some cases.¹⁵ These involuntary movements are not themselves a sign of pain, but they are frequently misinterpreted as suffering by family members at the bedside.

Why Pain in Liver Failure Is So Hard to Treat

Controlling pain in end-stage liver disease puts clinicians in a bind. The very organ responsible for processing most painkillers is the one that has failed. Common anti-inflammatory drugs like ibuprofen and naproxen carry heightened risks of gastrointestinal bleeding and kidney failure in this population, so they are generally avoided entirely.¹⁶ Acetaminophen, while often considered safer, has altered processing in a severely damaged liver, requiring careful dose reduction.

Opioids present their own problems. The liver normally breaks down opioids before they reach the bloodstream in full force. In cirrhosis, this first-pass metabolism is reduced, meaning a standard oral dose of morphine, oxycodone, or hydromorphone can hit the body much harder than intended.¹⁷ Some opioids also produce toxic byproducts that the failing liver cannot clear. Meperidine, for example, creates a metabolite that can cause seizures if it accumulates.¹⁶ Codeine presents the opposite problem: the liver must convert it into morphine for it to work at all, and a cirrhotic liver may fail at this conversion, leaving the drug ineffective.¹⁷

When opioids are used, immediate-release formulations are generally preferred over controlled-release ones, because the unpredictable metabolism makes long-acting drugs especially risky.¹⁸ There is also a persistent fear among clinicians that opioids will tip a patient into deeper encephalopathy. A small prospective study, however, found that cirrhotic patients receiving regular opioid therapy achieved adequate pain control without a significant increase in encephalopathy scores, with only two out of thirteen cirrhotic patients on opioids showing abnormal orientation results.¹⁹ That is one small study, not a definitive answer, but it does suggest the fear may be somewhat overblown and that careful opioid use is feasible.

The gap between need and relief is striking. In one retrospective study included in the meta-analysis, 90% of end-stage liver disease patients were prescribed something for pain, but only about a third achieved favorable relief, and three-quarters had already tried at least three different pain medications.¹ Pain in this disease is not merely present; it is stubbornly difficult to manage.

The Role of Depression and Anxiety

Pain in liver failure does not exist in a vacuum. Depression and anxiety amplify the experience in ways that can be hard to untangle from the physical disease itself. A study of cirrhosis patients undergoing transplant evaluation found that disease severity and its complications were not the primary predictors of how much pain patients reported. Instead, depression was the strongest predictor of both pain severity and pain interference with daily life.²⁰ In other words, two patients with the same degree of liver damage could report dramatically different pain experiences depending on their mental health.

Anxiety is also strikingly common in patients dealing with complications like variceal bleeding, where enlarged veins in the esophagus can rupture. A study of cirrhotic patients with upper gastrointestinal bleeding found that the majority showed anxiety symptoms on a validated screening tool, and that more severe varices correlated with greater psychological distress.²¹ Living with the knowledge that you could have a catastrophic bleed at any time creates a background hum of fear that colors the entire dying process, even during stretches when physical pain is controlled.

Palliative Care Gets Involved Too Late

One of the most frustrating findings in the literature is how infrequently patients with advanced liver disease receive palliative care compared to patients dying from other conditions. A Portuguese study comparing end-stage liver disease patients with cancer patients found that palliative care was offered to only about 19% of the liver disease patients, compared with 61% of cancer patients.²² Discussion of prognosis with the patient was also far less common in liver disease: only about 3% of liver patients had their prognosis discussed with them, compared with about 36% of cancer patients.²²

This disparity matters. When palliative care is introduced for liver disease patients, it improves not just pain but a whole constellation of symptoms. Patients who received palliative involvement showed improvements in itching, well-being, appetite, anxiety, fatigue, and depression.²³ The problem is not that comfort measures do not exist; it is that the disease’s unpredictable trajectory makes it harder for clinicians to identify the “right moment” to shift from curative-focused treatment. Many patients are still being considered for transplant or are undergoing aggressive treatments for complications, and the conversation about comfort can get deferred until very late.

What Children Experience

End-stage liver disease in children is far less common than in adults, but it does occur, often from biliary atresia or inherited metabolic conditions. The symptom profile overlaps heavily with adults. A retrospective study of children with spontaneous bacterial peritonitis, a serious infection that complicates liver failure, found that the symptoms were similar to those in adults: increased abdominal distension, fever, abdominal pain, vomiting, diarrhea, and encephalopathy.²⁴ The key difference is developmental: younger children cannot describe their pain clearly, and infants cannot report it at all, making assessment rely heavily on behavioral cues and clinician judgment. Pediatric palliative care teams, where they exist, play a critical role in bridging this communication gap.

What Families See Versus What Patients Feel

The final days of liver failure often look worse from the outside than they may feel from the inside, though certainty on this point is impossible. As encephalopathy deepens, patients pass through stages of increasing confusion, sleepiness, and eventual unresponsiveness. The sedative compounds accumulating in the blood, including ammonia and a tryptophan metabolite called oxindole with strong sedative properties, effectively create a kind of chemical sedation.¹² By the time a patient reaches deep hepatic coma, their awareness of pain and distress appears profoundly diminished, though, as with all forms of coma, absolute certainty about subjective experience is beyond the reach of current science.

What families observe during this transition, however, can be deeply distressing: jaundiced skin, a swollen abdomen, involuntary movements, changes in breathing pattern, and periods of agitation alternating with stillness. The physical distress frequently seen in the weeks and months before this final decline, the poorly controlled pain, the itching, the breathlessness, the repeated hospital procedures, tends to form the most painful part of the trajectory, both for the patient and for those watching. By the terminal hours, the disease itself often provides a degree of sedation that prescribed medications struggled to deliver earlier. That is cold comfort for families who watched their loved one suffer during the months leading up to it, but it is part of the honest picture.

1
PubMed Central. Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis
2
Gastro Hep Advances. Multidimensional Experience of Pain in Adults With Cirrhosis: A Cross-sectional Survey Study
3
PubMed Central. Symptom Distress in Patients with End-Stage Liver Disease toward the End of Life
4
PubMed Central. Glisson’s capsule matrix structure and function is altered in patients with cirrhosis irrespective of aetiology
5
PubMed Central. The assessment and management of pain in cirrhosis
6
PubMed Central. Hospice Care for End Stage Liver Disease in the United States
7
PubMed Central. Prevalence and morbidity associated with muscle cramps in patients with cirrhosis
8
PubMed Central. Drug treatment of pruritus in liver diseases
9
PubMed Central. Management of Pruritus in Chronic Liver Disease
10
Nature Reviews Gastroenterology & Hepatology. Mechanisms of pruritus in cholestasis: understanding and treating the itch
11
PubMed Central. Diagnosis and Management of Hepatic Hydrothorax
12
PubMed. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome
13
PubMed. Patients with manifest hepatic encephalopathy can reveal impaired thermal perception
14
PubMed Central. Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function
15
PubMed Central. Movement Disorders and Liver Disease
16
PubMed. Analgesics in patients with hepatic impairment: pharmacology and clinical implications
17
PubMed. Pharmacokinetics of opioids in liver disease
18
PubMed. Analgesia for the cirrhotic patient: a literature review and recommendations
19
Clinical and Experimental Hepatology. Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study
20
PubMed Central. The Complex Relationship Between Pain, Mental Health, and Quality-of-Life in Patients With Cirrhosis Undergoing Liver Transplant Evaluation
21
Deka in Medicine. Association between esophageal varices severity and psychological distress in cirrhotic patients
22
PubMed. Quality of death in patients in advanced chronic liver disease and cancer patients managed by gastroenterologists in Portugal: are we doing it right?
23
PubMed Central. How Do We Start Palliative Care for Patients With End-Stage Liver Disease?
24
Elsevier / Gastroenterology. Evaluation and Management of End-Stage Liver Disease in Children